Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
41 results about "Prostate cancer risk" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Prostate cancer risk factors. Some common risk factors for prostate cancer include: Race: Studies show that African American men are approximately 70 percent more likely to develop prostate cancer in their lifetime than Caucasian or Hispanic men. Age: The risk of developing prostate cancer increases with age.
Methods of improving screening, diagnosis and staging of prostate cancer using serum testosterone
InactiveUS20060211059A1Ultrasonic/sonic/infrasonic diagnosticsInfrasonic diagnosticsBiological bodySerum ige
The present invention provides methods of screening for, detecting or diagnosing prostate cancer in a subject by determining the level of prostate specific antigen (PSA), complexed PSA (cPSA), free PSA, B-PSA, PRO-PSA or HK2 in a biological sample from the subject and correcting this level for free / bioavailable serum testosterone, total testosterone or sex hormone binding globulin. The present invention further relates to identifying a subject at risk for developing prostate cancer or for determining the effectiveness of anti-cancer therapy in a subject having prostate cancer, or for detecting cancer recurrence by determining the level of prostate specific antigen (PSA), complexed PSA (cPSA), free PSA, B-PSA, PRO-PSA or HK2 in a biological sample from the subject and correcting this level for free or bioavailable serum testosterone, total testosterone or a testosterone bound protein, including but not limited to sex hormone binding globulin.
Owner:TANEJA SAMIR S
Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
InactiveUS7294704B2Reduce riskHigh profileAnimal cellsImmunoglobulins against cell receptors/antigens/surface-determinantsCancer cellMammal
Owner:DIAZYME LAB INC
Genetic variants contributing to risk of prostate cancer
InactiveUS20100041037A1Increased susceptibilityDetermining a susceptibility to prostate cancerBioreactor/fermenter combinationsBiological substance pretreatmentsOncologyProstate cancer risk
The present invention is characterised by certain genetic variants being susceptibility variants for prostate cancer. The invention relates to methods of determining increased susceptibility to prostate cancer, as well as methods of determining decreased susceptibility to prostate cancer, using such variants. The invention further relates to kits for determining a susceptibility to prostate cancer.
Owner:DECODE GENETICS EHF
Circulating insulin-like growth factor-I and prostate cancer risk
InactiveUS20010018190A1Improve the level ofIncreased riskPeptide/protein ingredientsHealth-index calculationInsulin-like growth factorIncreased risk
Methods of predicting a propensity to developing prostate cancer are presented. The method consists of measuring the IGF status of individual. Individuals with high IGF status, as compared with normal reference range values, are at increased risk for developing prostate cancer. More particularly, the IGF status may be determined by measuring IGF-I levels and / or IGFBP-3 levels. High IGF and low IGFBP levels are indicative of a high IGF status. A method of determining the prognosis of existing prostate cancers or of monitoring disease progression involves determining the IGF / PSA status of an individual. Individuals with a high IGF / PSA status (both high IGF status and high PSA levels) tend to develop severe prostate cancer and have a poorer overall prognosis.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC +1
Genetic Variants Contributing to Risk of Prostate Cancer
InactiveUS20110020320A1Increased susceptibilityGood health effectMicrobiological testing/measurementAntibody ingredientsOncologyProstate cancer risk
Owner:DECODE GENETICS EHF
Prostate cancer gene
The present invention relates to PG1, a gene associated with prostate cancer. The invention provides polynucleotides including biallelic markers derived from PG1 and from flanking genomic regions. Primers hybridizing to these biallelic markers and regions flanking are also provided. This invention provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and prostate cancer and between a haplotype and prostate cancer. The invention also relates to diagnostic methods of determining whether an individual is at risk for developing prostate cancer, and whether an individual suffers from prostate cancer as a result of a mutation in the PG1 gene.
Owner:SERONO GENETICS INST SA
Alternative splicing variants of genes associated with prostate cancer risk and survival
ActiveUS9453261B2High incidence and mortality rateIncreasing the short to long variants ratioTumor rejection antigen precursorsSugar derivativesCvd riskOncology
Disclosed are novel splicing variants of the genes associated with prostate cancer risk and survival, particularly splicing variants of PIK3CD, FGFR3, TSC2, RASGRP2, ITGA4, MET, NF1 and BAK1. The disclosure also relates risk assessment, detection, diagnosis, or prognosis of prostate cancer. More specifically, this disclosure relates to the detection of certain splicing variants of PIK3CD, FGFR3, TSC2, RASGRP2, ITGA4, MET, NF1 and BAK1.
Owner:GEORGE WASHINGTON UNIVERSITY
Methods and Compositions for Correlating Genetic Markers with Prostate Cancer Risk
ActiveUS20140057795A1Increased riskMicrobiological testing/measurementLibrary screeningPsa screeningAllelic polymorphism
The present invention provides methods of assessing an individual subject's risk of developing prostate cancer, comprising: a) analyzing a nucleic acid sample obtained from the subject and determining a genotype for the subject at a plurality of biallelic polymorphic loci, wherein each of said plurality has an associated allele and an unassociated allele, wherein the genotype is selected from the group consisting of homozygous for the associated allele, heterozygous, and homozygous for the unassociated allele; and b) calculating a cumulative relative risk (CRR) for the subject based on the genotype determined in step (a). A CRR of greater than 1.00 identifies a subject as having an increased risk of developing prostate cancer and also can identify a subject who is a candidate for early PSA screening, prostate biopsy and / or chemoprevention.
Owner:WAKE FOREST UNIV HEALTH SCI INC
Methods and compositions for correlating genetic markers with prostate cancer risk
InactiveUS20090226912A1Increased risk of developingIncreased riskMicrobiological testing/measurementSpecial data processing applicationsIncreased riskOncology
The present invention provides a method of identifying a subject as having an increased risk of developing prostate cancer, comprising detecting in the subject the presence of various polymorphisms associated with an increased risk of developing prostate cancer.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +2
Zinc-based screening test and kit for early diagnosis of prostate cancer
InactiveUS20070292900A1Improve stabilityHigh sensitivityBiological testingTesting metalsSemen sampleDiagnosis early
The present invention provides methods of determining if an individual is at risk for prostate cancer. The methods measures and compares free and / or bound zinc levels in a semen sample or prostatic fluid, including post massage expressed prostatic fluid, in the potential at risk individual with normal levels. A decrease in zinc level is indicative of a risk for prostate cancer.
Owner:ANDRO DIAGNOSTICS +1
Androgen-metabolic gene mutations and prostate cancer risk
This present invention identifies mutations in several androgen-metabolic genes (SRD5A2, CYP17, HSD3B2, and HSD17B3) and methods of using such mutations in the diagnosis and treatment of inheritable prostate cancer susceptibility. Isolation of genomic DNA of various racial / ethnic populations followed by SSCP scanning and direct PCR sequencing of the aberrant SSCP (single-strand conformation dependent DNA polymorphism) patterns allows for identification of the disclosed polymorphisms. Screening for the disclosed mutations establishes a differential distribution among various racial / ethnic groups as well as altered in vivo enzyme activity that parallels prostate cancer risk.
Owner:UNIV OF SOUTHERN CALIFORNIA
Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
ActiveUS20120178082A1Time-of-flight spectrometersMicrobiological testing/measurementGenetic markerProstate cancer risk
The present invention provides a method of identifying a subject as having an increased risk of having or developing aggressive prostate cancer, comprising detecting in the subject the presence of various polymorphisms associated with an increased risk of having or developing aggressive prostate cancer.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1
Metabolic biomarker for diagnosis and treatment of metastatic prostate cancer
ActiveUS20170067903A1Increase synthesisProcess is not compromisedOrganic active ingredientsPeptide/protein ingredientsProstate cancerCvd risk
Embodiments of the disclosure include methods and compositions for treatment of prostate cancer, including metastatic prostate cancer or prostate cancer at risk for developing into metastatic prostate cancer, by providing an effective therapy to an individual that has been determined to have elevated levels of SRC-2 (also known as NCOA2, GRIP1 TIF2). In particular cases, sample from an individual known to have prostate cancer is assayed for the risk for developing metastatic prostate cancer and the individual is provided an effective therapy upon determination of elevated levels of SRC-2.
Owner:BAYLOR COLLEGE OF MEDICINE
Methods and compositions to correlate trichomonas infection with prostate cancer
ActiveUS20070077606A1Increased risk of developingIncreased riskBiological testingΑ actininProstate cancer
The present invention provides methods and compositions for identifying a subject at increased risk of having prostate cancer by detecting an antibody that specifically binds a Trichomonas α-actinin protein in a sample of the subject.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Genetic polymorphisms in the prostate-specific antigen gene promoter
Owner:WAKE FOREST UNIV HEALTH SCI INC
Calcium supplementation to reduce prostate cancer risk
A method for promoting prostate health in a subject comprising administering a dose of calcium to the subject. Particularly provided is a method for reducing the risk of prostate carcinomas, comprising administering a dose of elemental calcium effective to reduce the risk of prostate cancer. In an example, 1200 mg of elemental calcium (supplied in 3000 mg of calcium carbonate) administered twice daily resulted in decreased risk of prostate cancer.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE
Methods and compositions for correlating genetic markers with prostate cancer risk
The present invention provides methods of assessing an individual subject's risk of developing prostate cancer, comprising: a) analyzing a nucleic acid sample obtained from the subject and determining a genotype for the subject at a plurality of biallelic polymorphic loci, wherein each of said plurality has an associated allele and an unassociated allele, wherein the genotype is selected from the group consisting of homozygous for the associated allele, heterozygous, and homozygous for the unassociated allele; and b) calculating a cumulative relative risk (CRR) for the subject based on the genotype determined in step (a). A CRR of greater than 1.00 identifies a subject as having an increased risk of developing prostate cancer and also can identify a subject who is a candidate for early PSA screening, prostate biopsy and / or chemoprevention.
Owner:WAKE FOREST UNIV HEALTH SCI INC
Transcriptional regulator combination
The invention relates to a method for treating androgen simulated diseases of a subject through delivering a combination containing an effective dose of I Kappa B kinase subunit alpha active inhibitors to the subject who needs treatment, which can also be used for reducing the risk of prostatic cancer of a subject through delivering the combination to the subject with high risk of prostatic cancer. The invention also relates to a method for recognizing a regulator of I Kappa B kinase subunit alpha regulated transcriptional activity. The invention also relates to a method for determining the I Kappa B kinase subunit alpha regulated transcriptional activity in nonhuman mammal test subjects.
Owner:ACAD SINIC
PRO108 Antibody Compositions and Methods of Use and Use of PRO108 to Assess Cancer Risk
InactiveUS20090232732A1Reduce riskHigh profileAnimal cellsImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesPsa antigen
This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In addition, it is directed to a method for assessing risk of ovarian, colon, breast or stomach cancer utilizing Pro108 or specific antibodies to Pro108. The invention provides isolated anti-prostate, ovarian, colon, breast or stomach cancer antigen (Pro108) antibodies that bind to Pro108 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro108 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro108 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro108 antibodies. The invention encompasses a method of producing the anti-Pro108 antibodies. Other aspects of the invention are a method of killing an Pro108-expressing cancer cell, comprising contacting Pro108 present in the ECM with an anti-Pro108 antibody and a method of alleviating or treating an Pro108-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro108 antibody to the mammal.
Owner:DIAZYME LAB INC
Prostatic cancer risk predicting device
InactiveCN105893782APromote early screeningConvenient diagnosis and treatmentHealth-index calculationSpecial data processing applicationsPuncture BiopsyEmergency medicine
The invention discloses a prostatic cancer risk predicting device which comprises an information collecting module, a risk predicting module and a result feedback module. The information collecting module is used for receiving related information and an examination result of a user, the risk predicting module is used for receiving data of the information collecting module, and the result feedback module is used for feeding a result of the risk predicting module back to the user and medical staff. The prostatic cancer risk predicting device is based on a prostatic risk predicting model suitable for Chinese people, so that early prediction of prostatic cancer risk of a patient is facilitated, and the prostatic cancer risk predicting device can prompt prostatic puncture biopsy as soon as possible; in addition, the prostatic cancer risk predicting device can realize background data collection and brings convenience to the medical staff to know information of the patient in details and to diagnosis and treatment. The prostatic cancer risk predicting device is wide in application range, the patient fills in information according to needs completely, and risk value of current prostatic cancer of individuals can be predicted; contact information can be further filled in for the convenience of contact between the medical staff and the patient. The prostatic cancer risk predicting device has great public health significance and economic value.
Owner:JIANGSU PROVINCE HOSPITAL
Device for predicting prostate cancer risk in prostate aspiration biopsy
InactiveCN105653886AAvoid overuseReach painHealth-index calculationSpecial data processing applicationsNewly diagnosedHealth index
Owner:FUDAN UNIV SHANGHAI CANCER CENT
Methods for detecting risk of fatal prostate cancer using serum calcium
A method of screening for increased risk of fatal prostate cancer in a subject comprises providing a blood sample collected from the subject, and then detecting the presence or absence of an increased level of serum calcium in the sample. An increased level of serum calcium indicates the subject is at increased risk of fatal prostate cancer.
Owner:WAKE FOREST UNIV HEALTH SCI INC
Alternative splicing variants of genes associated with prostate cancer risk and survival
ActiveUS20140364483A1High incidenceHigh mortality rateTumor rejection antigen precursorsSugar derivativesCvd riskOncology
Disclosed are novel splicing variants of the genes associated with prostate cancer risk and survival, particularly splicing variants of PIK3CD, FGFR3, TSC2, RASGRP2, ITGA4, MET, NF1 and BAK1. The disclosure also relates risk assessment, detection, diagnosis, or prognosis of prostate cancer. More specifically, this disclosure relates to the detection of certain splicing variants of PIK3CD, FGFR3, TSC2, RASGRP2, ITGA4, MET, NF1 and BAK1.
Owner:GEORGE WASHINGTON UNIVERSITY
Data storage device and method for determining the dependency of the risk for prostate cancer, device and method for indicating a risk for a disease of an individual
InactiveUS20090212551A1Low costSuffers riskOther printing matterHand manipulated computer devicesDiseaseMedicine
A data storage device comprises a memory in which a collection of prostate cancer screening data is stored. The screening data is obtained from a selection of the general male population without medical pre-selection. A device for indicating a risk for a disease of an individual, comprises an indicator for indicating a determined value for said risk. The indicator comprises a risk scale representing a range of values of said risk, and at least one dialler for entering a value of a diagnostic parameter of an individual. The dialler comprises a parameter scale representing a range of values of said diagnostic parameter. The dialler is movable with respect to said indicator such that when a parameter value on said parameter scale is selected, an associated risk value is indicated on said risk scale according to a predetermined mathematical relationship
Owner:STICHTING WETENSCHAPPELIJK ONDERZOEK PROSTAATKANKER SWOP
Methods for detecting risk of fatal prostate cancer using serum calcium
A method of screening for increased risk of fatal prostate cancer in a subject comprises providing a blood sample collected from the subject, and then detecting the presence or absence of an increased level of serum calcium in the sample. An increased level of serum calcium indicates the subject is at increased risk of fatal prostate cancer.
Owner:WAKE FOREST UNIV HEALTH SCI INC
Transcription regulating and controlling article composition
The invention relates to a method for treating an examinee with a male hormone exciting disease by adding a composition containing an effective dose of IkB kinase subunit alpha activity inhibitors. The invention also provides a method for reducing the risk of prostatic cancer of the examinee who is highly risky in getting the prostatic cancer by adding the composition. Another method relates to aregulator for identifying transcriptional activity regulated by the IkB kinase subunit alpha. Also another method relates to measure the transcriptional activity regulated by the IkB kinase subunit alpha in a nonhuman mammal testing examinee.
Owner:ACAD SINIC
Data storage device and method for determining the dependency of the risk for prostate cancer, device and method for indicating a risk for a disease of an individual
InactiveUS8087576B2Low costSuffers riskHand manipulated computer devicesOther printing matterDiseaseMedicine
A data storage device comprises a memory in which a collection of prostate cancer screening data is stored. The screening data is obtained from a selection of the general male population without medical pre-selection. A device for indicating a risk for a disease of an individual, comprises an indicator for indicating a determined value for said risk. The indicator comprises a risk scale representing a range of values of said risk, and at least one dialler for entering a value of a diagnostic parameter of an individual. The dialler comprises a parameter scale representing a range of values of said diagnostic parameter. The dialler is movable with respect to said indicator such that when a parameter value on said parameter scale is selected, an associated risk value is indicated on said risk scale according to a predetermined mathematical relationship.
Owner:STICHTING WETENSCHAPPELIJK ONDERZOEK PROSTAATKANKER SWOP
Prostate Cancer Diagnosis and Treatment Information Collection System
The invention relates to a prostate cancer diagnosis and treatment information collection system, and aims at solving the problem that the prostate cancer risk of some people is underestimated and the prostate cancer risk of some people is overestimated as PSA is clinically and frequently used for screening prostate cancer, the normal range of the PSA has a greater dispute and aspiration biopsy is carried out on the basis of simple PSA values. The invention provides a more comprehensive information collection system which is used for collecting and carrying out statistics on the basic medical history information, sera diagnosis information, image analysis information and prostate aspiration biopsy information of the prostate cancer patients, so as to re-summarize and re-measure the prostate cancer related indexes of the countrymen and provide prostate cancer detection indexes suitable for the countrymen for the clinic.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
Method and equipment for predicting postoperative biochemical relapse of prostate cancer patient
PendingCN113284619AImprove forecast accuracyImprove forecasting efficiencyHealth-index calculationForecastingClinico pathologicalPrediction probability
The invention relates to a method and equipment for predicting postoperative biochemical relapse of a prostate cancer patient. The method comprises the following steps: acquiring clinical pathological data of the prostate cancer patient, wherein the clinical pathology data at least comprise existence of IDC-P, age, NCCN standard prostate cancer risk classification and clinical T stage, and the clinical pathology data has certain correlation with the probability of biochemical recurrence of the prostate cancer patient. According to the clinical pathology data of the prostate cancer patient, based on a pre-trained prognosis model, a prediction probability of biochemical recurrence of the prostate cancer patient within a preset time is obtained. Prediction is performed through the prognosis model, compared with physicians, the prediction efficiency is higher, the prediction accuracy of the prognosis model can be continuously improved along with increase of sample data, and the prediction accuracy is higher compared with the physicians.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
Method Of Adjudicating On Prostate Cancer
InactiveUS20080020375A1Determined conveniently and highlySugar derivativesMicrobiological testing/measurementPrognostic predictionProstate cancer risk
The present invention relates to a method for determining a subject having a risk of having developed or developing prostate cancer, which comprises the following steps: a) a step of analyzing the presence / absence or level of mutation in the PCA-1 gene derived from the subject; and b) a step of evaluating the presence / absence or level of the subject's risk of having developed or developing prostate cancer, based on the presence / absence or level of mutation in the PCA-1 gene. According to the determination method of prostate cancer of the present invention, a subject having a risk of having developed or developing prostate cancer can be determined conveniently and highly sensitively. Therefore, the method is effective for the diagnosis of prostate cancer, progress monitoring, prognostic prediction, diagnosis before the onset, carrier diagnosis and the like.
Owner:YAMAMOTO HIROSHI +2
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com